The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Visual abstract | Efficacy of guselkumab in treating regional psoriasis and psoriatic arthritis: post-hoc analyses of VOYAGE 1 and 2
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
In post-hoc analyses of the VOYAGE 1 and 2 trials, what percentage of patients achieved scalp-specific Investigator’s Global Assessment (ss-IGA) score of 0/1 at Week 16 in the guselkumab group?
A
B
C
D
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing post-hoc analyses of the VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials assessing the efficacy of guselkumab in the treatment of regional psoriasis and psoriatic arthritis (PsA).
PsA is a chronic inflammatory condition with skin and musculoskeletal involvement. Patients with PsA and nail psoriasis have a poor quality of life, experiencing higher disease activity that makes treatment challenging. Guselkumab is an inhibitor of the p19 subunit of interleukin-23, approved for the treatment of moderate-to-severe psoriasis and active PsA in adults; guselkumab has demonstrated efficacy across multiple PsA domains in the DISCOVER-1 and DISCOVER-2 trials. The post-hoc analyses by Orbai et al.1 demonstrated that guselkumab was effective in treating psoriasis of nails, scalp, palms, and/or soles, and improved quality of life in patients with psoriasis and PsA.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
